A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer - Trial NCT06067841
Access comprehensive clinical trial information for NCT06067841 through Pure Global AI's free database. This Phase 1 trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
Phase 1
Oct 18, 2023
Jan 16, 2029
Primary Outcome
Number of participants with adverse events (AEs),Number of participants with serious adverse events (SAEs),Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria,Number of participants with AEs leading to study intervention discontinuation,Number of deaths
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of
 BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06067841
Non-Device Trial